(Q37685666)

22 August 2017

1 reference

title

From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease (English)

1 reference

22 August 2017

1 reference

Peter Jenner

1

1 reference

22 August 2017

1 December 2009

1 reference

Parkinsonism and Related Disorders

22 August 2017

1 reference

22 August 2017

15 Suppl 4

1 reference

22 August 2017

S18-23

1 reference

The history of dopamine and levodopa in the treatment of Parkinson's disease

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Dopamine agonists in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Molecular mechanisms of L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

How common are complications of Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Medical management of levodopa-associated motor complications in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

The etiology of Parkinson's disease with emphasis on the MPTP story

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

MPTP: insights into the etiology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Pharmacodynamic and Pharmacokinetic Features of Cabergoline

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Continuous dopaminergic stimulation in early and advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Continuous dopamine-receptor stimulation in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Beating a dead horse: dopamine and Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Nondopaminergic mechanisms in levodopa-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Non-dopaminergic treatments in development for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Advances in the delivery of treatments for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Translating A2A antagonist KW6002 from animal models to parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Early Parkinson's disease and non-motor issues

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Quantitation of non-motor symptoms in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970829-6

7 January 2021

10.1016/S1353-8020(09)70829-6

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20123550